<DOC>
	<DOCNO>NCT00806754</DOCNO>
	<brief_summary>- The primary objective study evaluate efficacy concomitant administration ciclesonide nasal spray azelastine nasal spray versus ciclesonide nasal spray alone patient ( 18 year old ) perennial allergic rhinitis ( PAR ) adequately control intranasal corticosteroid antihistamine monotherapy - The secondary objective investigate safety concomitant administration ciclesonide nasal spray azelastine nasal spray</brief_summary>
	<brief_title>Investigation Efficacy Safety Concomitant Administration Ciclesonide Nasal Spray Azelastine Nasal Spray Patients ( 18 Years Older ) With Perennial Allergic Rhinitis ( PAR ) Not Adequately Controlled Intranasal Corticosteroid Antihistamine Monotherapy ( BY9010/M1-490 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<mesh_term>Histamine Antagonists</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<criteria>1 . Male female , 18 year age old B0 Visit . 2 . General good health , free concomitant condition treatment investigator 's judgment could interfere study conduct , influence interpretation study observations/results , put patient increase risk trial . 3 . A history PAR minimum two year immediately precede Screening Visit ( B0 ) . The PAR must sufficient severity require treatment ( continuous intermittent ) past intranasal corticosteroid and/or antihistamine , investigator 's judgment , experience less complete symptom alleviation prior therapy . In addition , patient expect require treatment throughout study period . 4 . A demonstrated sensitivity least one allergen know induce PAR standard prick test within one year study start . A positive test define wheal diameter least 3 mm large control ( saline ) wheal prick test . Documentation positive result within 12 month prior Screening Visit ( B0 ) acceptable . 5 . Females childbearing potential currently use contraception must continue use medically reliable method contraception entire study duration ( e.g . oral , injectable , transcutaneous implantable contraceptive intrauterine device doublebarrier protection ) .Females sexually active must agree use doublebarrier protection become active course study . Women childbearing potential , less 1 year postmenopausal , require negative plasma pregnancy test Screening Visit ( B0 ) . Females consider nonchildbearing potential require urine pregnancy test least one follow apply : More one year postmenopausal Had hysterectomy Had bilateral ovariectomy salpingectomy tubal ligation Has congenital sterility 6 . Patients intranasal corticosteroid antihistamine stable dose least 4 week . 7 . Patients must complete 24hour reflective total nasal symptom assessment Screening Visit ( B0 ) score total 6 great ( 12 ) . 1 . Pregnancy , nursing , plan become pregnant donate gamete ( ova sperm ) vitro fertilization study period 30 day follow study period . 2 . History physical finding nasal pathology , include nasal polyp ( within last 60 day ) clinically significant respiratory tract malformation , recent nasal biopsy ( within last 60 day ) , nasal trauma , surgery atrophic rhinitis rhinitis medicamentosa ( within last 60 day ) . 3 . Participation investigational drug trial within 30 day precede Screening Visit . 4 . A known hypersensitivity intranasal corticosteroid , antihistamine excipients formulation . 5 . History respiratory infection disorder [ include , limited bronchitis , pneumonia , common cold , acute chronic sinusitis , flu , severe acute respiratory syndrome ( SARS ) ] within 14 day precede Screening Visit , development respiratory infection Screening Period . 6 . History alcohol drug abuse within precede two year . 7 . History positive test HIV , hepatitis B hepatitis C. 8 . Active asthma require treatment inhale systemic corticosteroid and/or routine use bagonists ; intermittent use bagonists acceptable . 9 . Use prohibit concomitant medication within prescribe ( per protocol ) time since last dose period prior Screening Visit ( B0 ) entire treatment duration . 10 . Use antibiotic therapy acute condition within 14 day prior Screening Visit ( B0 ) . Low dos antibiotic take prophylaxis permitted therapy start prior Screening Visit AND expect continue throughout trial . 11 . Initiation immunotherapy study period dose escalation study period . However , initiation immunotherapy 90 day prior Screening Visit AND use stable ( maintenance ) dose ( 30 day ) may consider inclusion . 12 . Nonvaccinated exposure active infection , chickenpox measles within 21 day precede Screening Visit ( B0 ) . 13 . Exposure systemic corticosteroid indication , chronic intermittent ( e.g . : contact dermatitis ) , past 2 month , presence underlying condition reasonably expect require treatment corticosteroid course study . 14 . Use topical corticosteroid concentration excess 1 % hydrocortisone dermatological condition past 1 month , presence underlying condition reasonably expect require treatment preparation course study . 15 . History epilepsy seizure ( exclude febrile seizure ) . 16 . History coronary artery disease , uncontrolled hypertension , clinically significant cardiovascular disease . 17 . Patients use combination treatment allergic rhinitis ( e.g . intranasal corticosteroid antihistamine ) . 18 . Have follow condition judge investigator clinically significant and/or affect subject 's ability participate clinical trial , might interfere study , require treatment make implementation protocol interpretation study result difficult : Impaired hepatic function include alcoholrelated liver disease cirrhosis ; History ocular disturbance e.g . glaucoma posterior subcapsular cataract ; Any systemic infection ; Hematological , hepatic , renal , endocrine ( except control diabetes mellitus postmenopausal symptom hypothyroidism ) ; Â· Gastrointestinal disease ; Malignancy ( exclude basal cell carcinoma ) . 19 . Clinical site employee immediate relative exclude study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Perennial Allergic Rhinitis</keyword>
	<keyword>Ciclesonide</keyword>
	<keyword>PAR</keyword>
</DOC>